Literature DB >> 12176665

Acipimox stimulates leptin production from isolated rat adipocytes.

Y-L Wang-Fisher1, J Han, W Guo.   

Abstract

Acipimox is a nicotinic acid-derived antilipolytic drug devoid of major side effects, and has been used in a number of human trials. This work reports the effects of Acipimox on leptin production from isolated rat adipocytes, in comparison with nicotinic acid and insulin. For cells isolated from normal animals, all these three reagents stimulated leptin release to a similar extent. Acipimox and nicotinic acid were more potent than insulin in stimulating leptin release from cells isolated from diabetic animals, probably because of impaired insulin sensitivity in cells from these diseased animals. Co-incubation of Acipimox with norepinephrine or dibutyryl cAMP diminished its stimulatory effects on leptin release, in parallel with increased lipolysis, suggesting that intracellular free fatty acids play an important role in mediating leptin production in adipocytes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12176665     DOI: 10.1677/joe.0.1740267

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  3 in total

Review 1.  Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia.

Authors:  Helen Vosper
Journal:  Br J Pharmacol       Date:  2009-07-20       Impact factor: 8.739

2.  A higher response of plasma neuropeptide Y, growth hormone, leptin levels and extracellular glycerol levels in subcutaneous abdominal adipose tissue to Acipimox during exercise in patients with bulimia nervosa: single-blind, randomized, microdialysis study.

Authors:  Kvido Smitka; Jara Nedvidkova; Hana Papezova; Karel Vondra; Martin Hill; Vojtech Hainer
Journal:  Nutr Metab (Lond)       Date:  2011-11-17       Impact factor: 4.169

3.  Adipocyte-conditioned medium induces resistance of breast cancer cells to lapatinib.

Authors:  A Geneste; M N Duong; L Molina; L Conilh; S Beaumel; A Cleret; K Chettab; M Lachat; L P Jordheim; E L Matera; C Dumontet
Journal:  BMC Pharmacol Toxicol       Date:  2020-08-14       Impact factor: 2.483

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.